Several studies in GBM revealed aberrant methylation patterns of specific genes, in addition to MGMT, and suggested that methylation profiles may be used to improve diagnostic accuracy and predict therapeutic responses (Wenger et al., 2019). This evidence concerns the gene MGMT and glioblastoma.